Pfizer Inc. (BVL:PFEUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 507.63B +10.1% |
| Revenue (ttm) | 220.96B +1.4% |
| Net Income | 26.14B -5.0% |
| EPS | 4.58 -5.1% |
| Shares Out | n/a |
| PE Ratio | 19.42 |
| Forward PE | 9.06 |
| Dividend | 5.90 (22.61%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 784 |
| Open | 26.10 |
| Previous Close | 26.22 |
| Day's Range | 26.00 - 26.10 |
| 52-Week Range | 23.40 - 28.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri
Pfizer (PFE) announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 Breakwater trial, evaluating Bratovi in combination with cetuximab and F...
Pfizer announces results from Phase 3 Talapro-3 study of Talzenna, Xtandi
Pfizer (PFE) announced detailed results from the Phase 3 Talapro-3 study of Talzenna, an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi, an androgen receptor pathway inhibitor, ...
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating...
Mailbag: A Follow-Up on Pfizer & Other Questions
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.
Pfizer announces seven-year follow-up results from Phase 3 CROWN trial
Pfizer (PFE) announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori in people with previously untreated, anaplastic lymphoma kinase-positi...
Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhi...
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in th...
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 ear...
Pfizer enters into global strategic collaboration with Innovent Biologics
Pfizer (PFE) and Innovent Biologics (IVBXF) announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new brea...
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic...
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
NEW YORK & SAN FRANCISCO & SUZHOU, China--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing...
Guardant Health to present 38 abstracts at ASCO 2026 meeting
Guardant Health (GH) announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer (PFE), showcasing advances in methylati...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at...
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a stra...
Pfizer announces pneumococcal conjugate vaccine candidate data
Pfizer (PFE) announced data from its Phase 2 study evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidat...
Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial
Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up to 15-fold higher antibody levels against a key strain...
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investi...
PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’
Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed that President Donald Trump is set to announce…
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and C...
Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
Pfizer price target raised to $26 from $25 at Wolfe Research
Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps an Underperform rating on the shares following what the firm calls…
Arvinas price target raised to $16 from $14 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps a Neutral rating on the shares. Arvinas and Pfizer (PFE) entered into…
European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI® (marstacimab) t...
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.